Dr. Wilfried Stücker is Managing Director of the IOZK and the IOZK Foundation. In 1985, he initiated today's Immuno-Oncology Center Cologne. In collaboration with various doctors and scientists, he developed the IOZK immunotherapy and set up the treatment center with the laboratories.
The IOZK Foundation was established in 2019 to optimize immunotherapies against cancer.
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Poster presentation at the annual meeting of the Association for Cancer Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report